JP2022547401A - 翼状片に関連した眼の見た目についての心配を軽減するための方法 - Google Patents

翼状片に関連した眼の見た目についての心配を軽減するための方法 Download PDF

Info

Publication number
JP2022547401A
JP2022547401A JP2022507861A JP2022507861A JP2022547401A JP 2022547401 A JP2022547401 A JP 2022547401A JP 2022507861 A JP2022507861 A JP 2022507861A JP 2022507861 A JP2022507861 A JP 2022507861A JP 2022547401 A JP2022547401 A JP 2022547401A
Authority
JP
Japan
Prior art keywords
patient
symptoms
reduction
reported signs
signs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022507861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547401A5 (OSRAM
Inventor
ジンソン ニ
スコット ウィトカップ
ロン ヤン
Original Assignee
クラウドブレイク セラピューティクス リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クラウドブレイク セラピューティクス リミテッド ライアビリティ カンパニー filed Critical クラウドブレイク セラピューティクス リミテッド ライアビリティ カンパニー
Publication of JP2022547401A publication Critical patent/JP2022547401A/ja
Publication of JP2022547401A5 publication Critical patent/JP2022547401A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Eye Examination Apparatus (AREA)
JP2022507861A 2019-09-10 2020-09-10 翼状片に関連した眼の見た目についての心配を軽減するための方法 Pending JP2022547401A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962898401P 2019-09-10 2019-09-10
US62/898,401 2019-09-10
PCT/US2020/050150 WO2021050692A2 (en) 2019-09-10 2020-09-10 Methods for alleviating pterygium-associated worry about eye appearance

Publications (2)

Publication Number Publication Date
JP2022547401A true JP2022547401A (ja) 2022-11-14
JP2022547401A5 JP2022547401A5 (OSRAM) 2023-09-19

Family

ID=74870040

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022507861A Pending JP2022547401A (ja) 2019-09-10 2020-09-10 翼状片に関連した眼の見た目についての心配を軽減するための方法

Country Status (10)

Country Link
US (1) US20220331310A1 (OSRAM)
EP (1) EP4027997A4 (OSRAM)
JP (1) JP2022547401A (OSRAM)
KR (1) KR20220061147A (OSRAM)
CN (1) CN114340618A (OSRAM)
AU (2) AU2020346812A1 (OSRAM)
BR (1) BR112021026662A2 (OSRAM)
CA (1) CA3146811A1 (OSRAM)
MX (1) MX2022000468A (OSRAM)
WO (1) WO2021050692A2 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2971096T3 (es) 2015-06-06 2024-06-03 Cloudbreak Therapeutics Llc Composiciones y métodos para tratar el terigio
CA3026118A1 (en) 2016-06-02 2017-12-07 Cloudbreak Therapeutics, Llc Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013188268A1 (en) * 2012-06-12 2013-12-19 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing pazopanib
JP2018521120A (ja) * 2015-06-06 2018-08-02 クラウドブレイク・セラピューティクス・エル・エル・シー 翼状片を治療するための組成物及び方法
JP2019517578A (ja) * 2016-06-02 2019-06-24 クラウドブレイク セラピューティクス リミテッド ライアビリティ カンパニー 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法
WO2019226864A1 (en) * 2018-05-25 2019-11-28 Scott Whitcup A composition for treating ocular hyperemia and a method for treating ocular hyperemia with the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100185564A1 (en) * 2009-01-21 2010-07-22 Mccormick & Company, Inc. Method and questionnaire for measuring consumer emotions associated with products
US8747852B1 (en) * 2012-12-28 2014-06-10 Randal Tanh Hoang Pham Methods of treating pterygium
CR20170566A (es) * 2015-06-09 2018-03-20 Bayer Pharma AG Moduladores alostéricos positivos del receptor muscarínico m2
TWI664965B (zh) * 2015-06-22 2019-07-11 新源生物科技股份有限公司 酪胺酸激酶抑制劑之眼用調配物、其使用方法、及其製備方法
CN108295072A (zh) * 2015-12-09 2018-07-20 瑞阳(苏州)生物科技有限公司 尼达尼布防治眼部疾病的用途
CA3010623A1 (en) * 2016-02-04 2017-08-10 Jinsong Ni Antibody-drug synergism technology for treating diseases
US11278546B2 (en) * 2016-07-22 2022-03-22 Aiviva Biopharma, Inc. Multikinase inhibitors and uses in ocular fibrosis
MX2019003623A (es) * 2016-09-28 2019-09-23 Medicon Pharmaceuticals Inc Composiciones y metodos para el tratamiento de afecciones oftalmicas.
CN116063221A (zh) * 2017-03-14 2023-05-05 新源生物科技股份有限公司 尼达尼布的晶型

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013188268A1 (en) * 2012-06-12 2013-12-19 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing pazopanib
JP2018521120A (ja) * 2015-06-06 2018-08-02 クラウドブレイク・セラピューティクス・エル・エル・シー 翼状片を治療するための組成物及び方法
JP2019517578A (ja) * 2016-06-02 2019-06-24 クラウドブレイク セラピューティクス リミテッド ライアビリティ カンパニー 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法
WO2019226864A1 (en) * 2018-05-25 2019-11-28 Scott Whitcup A composition for treating ocular hyperemia and a method for treating ocular hyperemia with the same

Also Published As

Publication number Publication date
CN114340618A (zh) 2022-04-12
EP4027997A2 (en) 2022-07-20
KR20220061147A (ko) 2022-05-12
WO2021050692A3 (en) 2021-05-14
AU2026202351A1 (en) 2026-04-16
US20220331310A1 (en) 2022-10-20
MX2022000468A (es) 2022-02-03
CA3146811A1 (en) 2021-03-18
BR112021026662A2 (pt) 2022-04-12
WO2021050692A2 (en) 2021-03-18
AU2020346812A1 (en) 2022-01-27
EP4027997A4 (en) 2023-10-11

Similar Documents

Publication Publication Date Title
Celik et al. Accelerated corneal crosslinking concurrent with laser in situ keratomileusis
Salman Transepithelial corneal collagen crosslinking for progressive keratoconus in a pediatric age group
Landers et al. Treatment of retinopathy of prematurity with argon laser photocoagulation
Iqbal et al. Standard cross‐linking versus photorefractive keratectomy combined with accelerated cross‐linking for keratoconus management: a comparative study
JP2020530470A (ja) 老化細胞を排除する薬学的作用物質を用いる、黄斑変性症、緑内障、および糖尿病性網膜症などの眼病態の治療
MX2011002234A (es) El uso de intensificadores, posiblemente asociados con riboflavina, asi como composiciones oftalmicas correspondientes para la reticulacion de la cornea, en el tratamiento de queratocono o de otras alteraciones ectasicas de la cornea.
EP3886858B1 (en) Compounds for treatment of eye diseases associated with excessive vascularisation
Iqbal et al. Evaluation of the effectiveness of cross-linking combined with photorefractive keratectomy for treatment of keratoconus
US10918719B2 (en) Methods for cross-linking corneal collagen with verteporfin for the treatment of disorders of the eye
Förster et al. Therapeutic use of the 193-nm excimer laser in corneal pathologies
Seitz et al. The penetrating keratoplasty (PKP): a century of success
AU2026202351A1 (en) Methods for alleviating pterygium-associated worry about eye appearance
Knorz et al. Treatment of myopia and myopic astigmatism by customized laser in situ keratomileusis based on corneal topography
Alasmari et al. Transepithelial photorefractive keratectomy to treat mild myopia
Chanbour et al. Corneal cross-linking for keratoconus and post-LASIK ectasia and failure rate: a 3 years follow-up study
Rymer et al. Pain response and symptoms in photorefractive keratectomy: mechanical de-epithelization compared with transepithelial ablation
Chelala et al. The role of topical vitamin A in promoting healing in surface refractive procedures: a prospective randomized controlled study
Abdel-Radi et al. Preservative-free topical anesthetic unit-dose eye drops for the management of postoperative pain following photorefractive keratectomy
Toyos Comparison of once-daily bromfenac 0.07% versus once-daily nepafenac 0.3% in patients undergoing phacoemulsification
Seyyar et al. Outcomes of customized topographic guided epithelial debridement for corneal collagen cross-linking
O’Brart Corneal collagen cross-linking for corneal ectasias
HK40068230A (en) Methods for alleviating pterygium-associated worry about eye appearance
Czumbel et al. A phase III, multicentre, randomised, investigator-masked, cross-over, comparative, non-inferiority trial evaluating the efficacy and tolerability of generic preservative-free Latanoprost (Polpharma SA) compared to Xalatan®(Pfizer) in patients with ocular hypertension or primary open-angle glaucoma
Yu et al. Randomized controlled trial on corneal denervation, neuroinflammation and ocular surface in corneal lenticule extraction for advanced refractive correction (CLEAR) and small incision lenticule extraction (SMILE)
Humayun et al. Mechanical epithelial debridement< em> versus transepithelial phototherapeutic keratectomy followed by accelerated corneal collagen crosslinking for progressive keratoconus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220309

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240725

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260423